Search
sparsentan (Filspari)
Indications:
- treatment of adults with primary IgA nephropathy*
* accelerated FDA-approval
Contraindications:
- pregnancy
Dosage:
- 400 mg PO QD
Tablets: 200 mg, 400 mg
Adverse effects:
* black box warning: potential hepatotoxicity & embryo-fetal toxicity
Mechanism of action:
- non-immunosuppressive therapy
- dual endothelin angiotensin receptor antagonist
- selectively targets the endothelin A receptor & the angiotensin II subtype 1 receptor.
Notes:
- restricted-distribution program (participation required)
Interactions
drug adverse effects of angiotensin II receptor antagonists
monitor with ARBs
General
angiotensin II receptor antagonist (ARB)
endothelin receptor antagonist
Database Correlations
PUBCHEM correlations
References
- Zoler ml
FDA OKs Sparsentan for Rare Kidney Disease.
Medscape. Feb 20, 2023
https://www.medscape.com/viewarticle/988482
- HIGHLIGHTS OF PRESCRIBING INFORMATION
Filspari (sparsentan) tablets, for oral use
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216403s000lbl.pdf